David M. Goldenberg

39.9k citations

745 papers · 28.2k indexed · 4 hit papers · h-index 85

Impact in

Radiology, Nuclear Medicine and Imaging top 0.01%
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
Oncology top 0.05%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis

Papers in

Radiology, Nuclear Medicine and Imaging 526
- Monoclonal and Polyclonal Antibodies Research 377
- Radiopharmaceutical Chemistry and Applications 370
- Medical Imaging Techniques and Applications 45
Oncology 257
- HER2/EGFR in Cancer Research 87
- Peptidase Inhibition and Analysis 48

Co-authors: Robert M. Sharkey Chien‐Hsing Chang Hans J. Hansen Edmund A. Rossi Thomas M. Cardillo William J. McBride Rhona Stein Serengulam V. Govindan
Journals: Journal of Clinical Oncology (58 papers)Blood (56 papers)Cancer (44 papers)Cancer Research (36 papers)International Journal of Cancer (32 papers)
Partner nations: United States Germany Netherlands

In The Last Decade

David M. Goldenberg

737 papers receiving 27.2k citations

Hit Papers

align trajectories log scale

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer 2019 · 599 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 New England Journal of Medicine
2015 Oncotarget
2010 Ultrasound in Medicine & Biology
1978 New England Journal of Medicine

Peers

Countries citing papers authored by David M. Goldenberg

Since Specialization

Citations

This map shows the geographic impact of David M. Goldenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Goldenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Goldenberg more than expected).

Fields of papers citing papers by David M. Goldenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Goldenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Goldenberg. The network helps show where David M. Goldenberg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David M. Goldenberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David M. Goldenberg Line = papers co-authored together David M. Goldenberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells Cancer Research ·Chien‐Hsing Chang, Yang Wang, Rongxiu Li, Diane L. Rossi, Donglin Liu, Edmund A. Rossi, Thomas M. Cardillo, David M. Goldenberg	2017	67
2	Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan Journal of Clinical Oncology ·Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters, W. Thomas Purcell, Alexander Starodub, Leora Horn, Ronald Scheff, Aditya Bardia, Wells A. Messersmith, Jordan Berlin, Allyson J. Ocean, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg, D. Ross Camidge	2017	139
3	Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130) Molecular Cancer Therapeutics ·Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, Helena Sofia Almeida Miranda, Jing Xia, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg	2017	24
4	IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma Molecular Cancer Therapeutics ·Thomas M. Cardillo, Serengulam V. Govindan, Ning Li, Diane L. Rossi, Yang Wang, Chien‐Hsing Chang, David M. Goldenberg	2017	21
5	Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers Molecular Cancer Therapeutics ·Chien‐Hsing Chang, Yang Wang, Ning Li, Donglin Liu, Thomas M. Cardillo, David M. Goldenberg	2016	42
6	Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan) Clinical Cancer Research ·Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Serengulam V. Govindan, Yang Wang, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg	2015	130
7	First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors Clinical Cancer Research ·Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Linda T. Vahdat, Sajeve Thomas, Serengulam V. Govindan, Pius Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg	2015	252
8	Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α Molecular Cancer Therapeutics ·Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien‐Hsing Chang, David M. Goldenberg	2014	20
9	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab Blood ·Edmund A. Rossi, David M. Goldenberg, Rosana Michel, Diane L. Rossi, Daniel J. Wallace, Chien‐Hsing Chang	2013	88
10	Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies Clinical Cancer Research ·Yicheng Mao, Georgia Triantafillou, Erin Hertlein, William H. Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch A. Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, Natarajan Muthusamy	2012	26
11	Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies Molecular Cancer Therapeutics ·Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, David M. Goldenberg	2011	50
12	Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models Molecular Cancer Therapeutics ·Robert M. Sharkey, Habibe Karacay, Serengulam V. Govindan, David M. Goldenberg	2011	40
13	A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells Cancer Research ·Edmund A. Rossi, Diane L. Rossi, Rhona Stein, David M. Goldenberg, Chien‐Hsing Chang	2010	39
14	Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells Molecular Cancer Therapeutics ·Chien‐Hsing Chang, Pankaj Gupta, Rosana Michel, 艾华, Yang Wang, Thomas M. Cardillo, David M. Goldenberg	2010	43
15	CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas Blood ·Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien‐Hsing Chang	2009	57
16	The Curse of Ham Princeton University Press eBooks ·David M. Goldenberg	2009	68
17	Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non–Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody Cancer Research ·Robert M. Sharkey, Habibe Karacay, Samuel Litwin, Edmund A. Rossi, William J. McBride, Chien‐Hsing Chang, David M. Goldenberg	2008	60
18	A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma Cancer Research ·David V. Gold, David M. Goldenberg, Habibe Karacay, Edmund A. Rossi, Chien‐Hsing Chang, Thomas M. Cardillo, William J. McBride, Robert M. Sharkey	2008	53
19	Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics Cancer Research ·Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Yang Wang, Chien‐Hsing Chang	2008	49
20	Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts Molecular Cancer Therapeutics ·Alice P. Taylor, David M. Goldenberg	2007	57

About David M. Goldenberg

David M. Goldenberg is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Pathology and Forensic Medicine, Immunology and Genetics, having authored 745 papers that have together received 28.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (377 papers), Radiopharmaceutical Chemistry and Applications (370 papers), Lymphoma Diagnosis and Treatment (135 papers), HER2/EGFR in Cancer Research (87 papers), Glycosylation and Glycoproteins Research (59 papers), Peptidase Inhibition and Analysis (48 papers), Neuroendocrine Tumor Research Advances (47 papers) and Medical Imaging Techniques and Applications (45 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (16.3k citations), Oncology (10.8k citations), Pathology and Forensic Medicine (3.9k citations), Immunology (4.3k citations) and Genetics (1.7k citations). David M. Goldenberg has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Robert M. Sharkey, Chien‐Hsing Chang, Hans J. Hansen, Edmund A. Rossi, Thomas M. Cardillo, William J. McBride, Rhona Stein, Serengulam V. Govindan, Rosalyn D. Blumenthal and F. James Primus. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer, Cancer Research and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact